VBI Vaccines shares up on positive VBI-2601 data in chronic hep B

• VBI shares rose after interim results from ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.
• Interim data from low-dose cohorts achieved human proof-of-concept, demonstrating restoration of both antibody and T cell responses in chronic HBV patients.
• Potent re-stimulation of T cell responses to HBV surface antigens seen in 67% (n=6/9) and 78% (n=7/9) of evaluable patients in the low-dose VBI-2601 unadjuvanted and adjuvanted study arms, respectively.
• Antibody responses against HBV surface antigens were observed in 60% of evaluable patients (n=6/10) in unadjuvanted cohort and in 67% (n=6/9) in adjuvanted cohort
• Low dose immunotherapeutic was well-tolerated with no safety signals observed.
• The two-part dose-escalation study assessing a low dose and a high dose of VBI-2601 has enrolled 46 patients.
• Data from the high-dose cohorts expected in Q1 2021.
• https://seekingalpha.com/news/3637462-vbi-vaccines-shares-up-4-on-positive-vbiminus-2601-data-in-chronic-hepatitis-b-virus